3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
4
Lung Neoplasms
4
Recurrence
3
Non Small Cell Lung Cancer Metastatic
3
Meningeal Carcinomatosis
2
Brain Neoplasms
2
Thrombocytosis
1
Sexual Dysfunction, Physiological
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoadjuvant Non-Small Cell Lung Cancer
1
NSCLC
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Carboplatin
10
Paclitaxel
5
Nivolumab
4
Pemetrexed
3
Cisplatin
3
atezolizumab
2
apatinib
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Blood Specimen Collection
2
Bevacizumab
2
zimberelimab
1
toripalimab
1
spartalizumab
1
sitravatinib
1
sintilimab
1
sacituzumab govitecan
1
pembrolizumab
1
lorlatinib
1
cemiplimab
1
camrelizumab
1
Vital Signs
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Telescopes
1
Talc
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Diseases
×
lorlatinib
×
Clear all
NCT05167500
2023-03-30
LORLAPULM
Fundación GECP
Completed
118 enrolled